Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Oxodotreotide
Plasma Cell Myeloma
Jules Bordet Institute
P1
CC
(43)
Oxodotreotide
Nasopharyngeal Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Oxodotreotide
Olfactory Neuroblastoma
National Cancer Institute (NCI)
P1
CC
(43)
Oxodotreotide
Pancreatic Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Oxygen
Cluster Headache Syndrome
The University of Texas Health Science Center, Houston
P1
CC
(43)
Oxygen
Hemicrania Continua
The University of Texas Health Science Center, Houston
P1
CC
(43)
Oxygen
Paroxysmal Hemicrania
The University of Texas Health Science Center, Houston
P1
CC
(43)
Oxygen
SUNCT Syndrome
The University of Texas Health Science Center, Houston
P1
CC
(43)
Oxygen
Trigeminal Autonomic Cephalalgia
The University of Texas Health Science Center, Houston
P1
CC
(43)
p95her2.car-tech2me
Endometrial Cancer
Vall d'Hebron Institute of Oncology
P1
CC
(43)
p95her2.car-tech2me
Gastric Cancer
Vall d'Hebron Institute of Oncology
P1
CC
(43)
Pace Cart19
Acute Lymphoblastic Leukemia
University of Pennsylvania
P1
CC
(43)
Pace Cart19
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
University of Pennsylvania
P1
CC
(43)
Pace Cart19
Non-Hodgkin Lymphoma
University of Pennsylvania
P1
CC
(43)
Palazestrant
Metastatic Prostate Carcinoma
Olema Pharmaceuticals, Inc.
P1
CC
(43)
Palazestrant
Non-Small Cell Lung Carcinoma
Olema Pharmaceuticals, Inc.
P1
CC
(43)
Palbociclib
Amyotrophic Lateral Sclerosis Type 19
M.D. Anderson Cancer Center
P1
CC
(43)
Palbociclib
Retinoblastoma
Brown University
P1
CC
(43)
Pamiparib
Low Grade Glioma
University of California, San Francisco
P1
CC
(43)
Panda-Vac
Head And Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
P1
CC
(43)
Panda-Vac
Squamous Cell Lung Carcinoma
UNC Lineberger Comprehensive Cancer Center
P1
CC
(43)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Ureter Transitional Cell Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Malignant Renal Pelvis Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Showing 3701 to 3725 of 9,920 assets
Previous
Page 149 of 397
Next